Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
BMC Cancer. 2017 Sep 1;17(1):610. doi: 10.1186/s12885-017-3629-2.
Molecular biomarkers capable of predicting recurrence patterns and prognosis are helpful for risk stratification and providing appropriate treatment to patients with hepatocellular carcinoma (HCC). In this study, we focused on G protein-coupled receptor 155 (GPR155), a cell surface signaling protein, as a candidate biomarker.
We analyzed GPR155 expression, DNA methylation, and copy number in HCC cell lines. The clinical significance of GPR155 expression was evaluated using 144 pairs of surgically resected liver and normal tissues with subgroup analysis based on hepatitis virus infection.
GPR155 mRNA expression levels were differential and were decreased in 89% of HCC cell lines. No DNA methylation was detected, whereas copy number alterations were present in five (56%) HCC cell lines. GPR155 mRNA expression level was independent of background liver status and significantly lower in HCC tissues than corresponding normal liver tissues. The expression patterns of GPR155 protein by immunohistochemical staining were significantly associated with those of GPR155 mRNA. Downregulation of GPR155 was significantly associated with more aggressive HCC phenotypes including high preoperative α-fetoprotein, poor differentiation, serosal infiltration, vascular invasion, and advanced disease stage. Patients with downregulation of GPR155 were more likely to have worse prognosis after curative resection irrespective of hepatitis virus infection. Patients who experienced extrahepatic (distant) recurrences had significantly lower GPR155 expression than those with intrahepatic (liver confined) recurrences.
Downregulation of GPR155 may serve as a prognosticator that also predicts initial recurrence sites independent of hepatitis virus infection.
能够预测复发模式和预后的分子生物标志物有助于对肝细胞癌(HCC)患者进行风险分层并提供适当的治疗。在这项研究中,我们专注于 G 蛋白偶联受体 155(GPR155),一种细胞表面信号蛋白,作为候选生物标志物。
我们分析了 HCC 细胞系中的 GPR155 表达、DNA 甲基化和拷贝数。根据肝炎病毒感染情况进行亚组分析,评估 GPR155 表达的临床意义。
GPR155 mRNA 表达水平存在差异,89%的 HCC 细胞系表达降低。未检测到 DNA 甲基化,但在 5(56%)个 HCC 细胞系中存在拷贝数改变。GPR155 mRNA 表达水平与背景肝状态无关,在 HCC 组织中明显低于相应的正常肝组织。免疫组织化学染色的 GPR155 蛋白表达模式与 GPR155 mRNA 的表达模式显著相关。GPR155 的下调与更具侵袭性的 HCC 表型显著相关,包括术前 α-胎蛋白水平高、分化差、浆膜浸润、血管侵犯和疾病分期较晚。根治性切除术后,GPR155 下调的患者无论是否感染肝炎病毒,预后均较差。发生肝外(远处)复发的患者的 GPR155 表达明显低于发生肝内(肝脏局限)复发的患者。
GPR155 的下调可能作为一种预后标志物,独立于肝炎病毒感染预测初始复发部位。